The Pharma Data

NOVEMBER 22, 2020

Scientists in Israel have used the CRISPR Cas-9 gene editing system to destroy cancerous cells in mice without damaging other cells. The product is the most advanced gene-editing approach in development for transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease. ” Source link.

Gene Editing 52

Gene Editing DNA Genomics Genome 52

The Pharma Data

JANUARY 19, 2021

A naturally occurring system for tuning CRISPR-Cas9 expressing in bacteria, identified in a study published in Cell , could have implications for gene editing therapies as well.

Bacteria 52

Bacteria Gene Editing Research RNA 52

The Pharma Data

DECEMBER 13, 2020

which develops genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of diseases, today announced the appointment of Bo Zhang, Ph.D., 14, 2020 10:00 UTC. BEIJING & CAMBRIDGE, Mass.–( –( BUSINESS WIRE )– EdiGene, Inc. as Head of Business Development. “Our

Business Development 40

Business Development Development Gene Editing In-Vivo 40

pharmaphorum

APRIL 20, 2022

The potential to develop treatments with CRISPR gene editing is hinged on its ability to add, delete or replace elements within a target DNA sequence. The potential for CRISPR gene editing to offer a therapeutic option to patients is clear, based on its mechanism, but there are already gene editing therapeutics on the market.

Gene Editing 52

Gene Editing DNA Gene Genetics 52

XTalks

NOVEMBER 3, 2023

CRISPR works as genetic scissors to edit parts of the genome. The CRISPR-Cas9 gene editing system was first discovered to be endogenous in bacteria. Given the system’s powerful ability to make cuts in genes in a precise manner, the system is being leveraged in gene therapies.

Gene Therapy 59

Gene Therapy Gene Gene Editing In-Vivo 59

The Pharma Data

JANUARY 24, 2021

. “We are excited to welcome Chris, a highly regarded drug developer and team builder who brings to Notch great depth of experience and expertise in development of cell therapies, gene editing, and cell engineering spanning discovery through IND,” said David Main , President and Chief Executive Officer of Notch.

Engineer 52

Engineer Gene Editing Genomics Genome 52

Delveinsight

SEPTEMBER 14, 2021

The outcomes will also be utilized to transition ADARx’s growing pipeline of research phase products into the clinic, initiating Phase 1 clinical trials for ADARx’s lead program. VOR33 comprises CRISPR genome-edited hematopoietic stem and progenitor cells , which have been engineered to exclude CD33.

RNA 67

RNA Clinical Trials Clinical Trials Drugs 67

pharmaphorum

AUGUST 25, 2022

Explore approaches to boost safe gene-editing, approach regulatory affairs, turbocharge scale-up, optimize analytics and more to produce best-in-class therapies for immuno-oncology and regenerative medicine. Sana Biotechnology , Takeda and many more.

Gene Editing 40

Gene Editing Genomics Genome Engineer 40

The Pharma Data

FEBRUARY 22, 2021

Gene editing investments advance agriculture with improved food quality, higher yield, and improved crop nutrition. Gene editing is the key to better solutions and greater choices for farmers and consumers around the world.

Gene Editing 40

Gene Editing Genomics Genome Protein 40

Delveinsight

JANUARY 14, 2021

Both companies retain full rights to their product candidates and discuss the potential path forward for any future combination studies based on the outcome of the Phase 2 trial. Eligible members will get an integrated product experience, comprising the Livongo for Diabetes program, Dexcom CGM technology, and CGM-powered insights at no cost.

Gene Editing 40

Gene Editing Gene Genetics DNA 40

Advarra

NOVEMBER 29, 2022

Recent Problems in Cell and Gene Therapy Development. Dealing with confusing regulatory guidelines is one of the top obstacles researchers face as they develop CGT products 1. In the last two years, there haven’t been any CGT product approvals, primarily because of the COVID-19 pandemic.

Gene Therapy 52

Gene Therapy Gene Production Clinical Trials 52

Delveinsight

AUGUST 27, 2020

As observed in 45 younger adults, the middle dose of the vaccine triggered the production of neutralizing antibodies against SARS-CoV-2, the virus, which causes COVID-19 , in 10 patients aged 56 to 70 and 10 patients over 71. Targeted drug combo attacks breast cancer brain metastases in mice.

Vaccination 53

Vaccination Vaccine Research Trials 53

The Pharma Data

NOVEMBER 3, 2020

The FDA’s Fast Track designation is a process designed to expedite or facilitate the review of product candidates to treat serious conditions and fill an unmet medical need. LogicBio is also developing a Next Generation Capsid platform for use in gene editing and gene therapies. A bout Fast Track Designation.

Clinical Trials 40

Clinical Trials Clinical Trials Gene Editing Genomics 40

Pharmaceutical Technology

FEBRUARY 13, 2023

This is particularly the case for pediatric forms of epilepsy where gene editing techniques like Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) are becoming more important, says Ferraro. To tackle this, companies have developed different ways to focus on the gene.

Research 264

Research Gene Gene Therapy Genomics 264

The Pharma Data

JANUARY 10, 2021

Nasdaq: EDIT), a leading genome editing company, today announced the U.S. Food and Drug Administration (FDA) has cleared the initiation of the safety phase of the Company’s EDIT-301 clinical trial, and the Company can begin dosing patients. Enrolled patients will receive a single administration of EDIT-301.

Medicine 52

Medicine Development Clinical Trials Clinical Trials 52

Cloudbyz

MARCH 6, 2024

Moreover, the rise of biologics has spurred advancements in manufacturing technologies, such as cell culture systems and bioreactors, enabling the large-scale production of complex biological molecules. Looking ahead, the future of pharmaceutical therapies is undeniably intertwined with the continued advancement of biologics.

Gene 99

Gene Immune Response Manufacturing Gene Therapy 99

XTalks

NOVEMBER 30, 2023

to 10-fold relative to baseline within 28 days after the cell product infusion. These findings signify a significant step forward in the development of AGT103-T as a potential gene therapy for HIV. Additionally, Gag-specific CD8+ T cells demonstrated an increase of 1.7

FDA Approval 111

FDA Approval Gene Therapy Gene Clinical Trials 111

pharmaphorum

FEBRUARY 3, 2021

Dr Jennifer Harbottle, senior scientist in the R&D Base Editing team of PerkinElmer’s Horizon Discovery business, looks at progress made in the realms of biotechnology and next-generation diagnostics, vaccines and therapeutics, including the application of CRISPR-Cas9 gene editing in developing and refining cell therapies.

Gene Editing 98

Gene Editing Gene DNA Engineer 98

Pharma Marketing Network

JANUARY 20, 2021

Regarding the use of direct-acting anti-SARS-CoV-2 therapeutics (such as nucleoside analogs, protease inhibitors, and monoclonal antibodies), the panel stressed the need for constant surveillance to track changes in the viral genome that might result from their use.

Vaccination 52

Vaccination Vaccine In-Vivo Genetics 52

Pharmaceutical Technology

FEBRUARY 20, 2023

He says these issues must be urgently addressed over the next few years as advancing medical knowledge and the role of genomics in treating disease ushers in a new era of precision medicine and new potential to address diseases that affect certain populations. The technology platforms are almost the same.

Research 130

Research Clinical Trials Clinical Trials Trials 130

XTalks

SEPTEMBER 21, 2020

A female’s second X chromosome is typically silenced (so that females don’t get an overdose of X chromosome genes) through X-linked inactivation, a process where the chromosome is coated with an outer layer of non-coding RNA. One of these doubly active genes is KDM6A.

Gene 89

Gene Protein Gene Expression Scientist 89

The Pharma Data

DECEMBER 2, 2020

ERS Genomics – Ireland’s ERS Genomics Limited, and Germany’s Vivlion GmbH, announced a non-exclusive license agreement granting Vivlion access to ERS Genomics’ CRISPR/Cas9 patent portfolio, to enhance Vivlion’s gene editing reagents and screening services. Financial details of the agreement were not disclosed.

Drugs 52

Drugs Gene Editing Genomics Genome 52

XTalks

DECEMBER 24, 2020

From isolating SARS-CoV-2 in early January to sequencing its genome shortly thereafter and having a prototype vaccine against it within days, scientific process and progress have held steadfast throughout the pandemic. Infectious disease expert, epidemiologist and director of the Yale Institute for Global Health at Yale University, Saad B.

Life Science 111

Life Science Vaccination Vaccine Gene 111

XTalks

JANUARY 6, 2025

Medical device manufacturers are leveraging these technologies to enhance their products, supporting healthcare providers and improving patient outcomes. Additionally, CRISPR genome-wide screening holds great potential for identifying key disease-associated genes and uncovering novel therapeutic targets.

Gene Therapy 111

Gene Therapy RNA Gene Editing Gene 111